DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)
This study tests a new drug called DZD8586, either alone or combined with other treatments, in patients with diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Researchers will measure how well the drug works at shrinking tumors and monitor patients for side effects.
Key Objective: This trial is testing whether DZD8586 combination therapy can effectively treat DLBCL while being safe and tolerable for patients.
Who to Consider: Patients diagnosed with diffuse large B-cell lymphoma who are interested in exploring a novel treatment option should consider enrolling.
Trial Parameters
Brief Summary
This study will treat patients with diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of DZD8586 combination therapy by using objective response rate and the incidence and severity of adverse events. It will also measure the levels of DZD8586 in the body when combined with immunochemotherapy regimens.
Eligibility Criteria
Inclusion Criteria: * Cohort 1: 1. Patients with pathologically confirmed DLBCL who have not received prior anti-lymphoma therapy. 2. Disease stage II to IV by Ann Arbor Classification. 3. Life expectancy ≥ 12 months. * Cohort 2, 3: 1. Pathologically confirmed DLBCL patients who have received adequate first-line treatment containing CD20 monoclonal antibody and anthracyclines (such as R-CHOP-like regimen). 2. Relapsed or refractory to first-line R-CHOP-like regimen. 3. For patients who have received only one line of therapy, if the patient has not received autologous stem cell transplantation, the investigator needs to assess as unsuitable or the patient refuses intensive chemotherapy and hematopoietic stem cell transplantation. 4. Life expectancy ≥ 6 months. * Patients must also meet all of the following criteria to be included in this study: 1. All patients must provide a signed and dated written informed consent prior to any study-specific procedure, sampling, and analysis. 2. Patie